Brief: Ultimovacs Q3 Oper Profit At NOK 54.7 Mln

Zelluna ASA

08/11/2023 07:09

Nov 8 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * Q3 TOTAL OPERATING EXPENSES MNOK 54.7 AND MNOK 156.1 YTD
    * Q3 OPERATING LOSS MNOK 55.8 AND MNOK 133.3 YTD
    * IF ONGOING CLINICAL DEVELOPMENT AND TESTING OF ULTIMOVACS’
CANCER VACCINE UV1 PROVIDES CLINICAL BENEFIT TO CANCER PATIENTS,
POTENTIAL CLINICAL USE OF UV1 AND RELATED FINANCIAL BENEFITS
COULD BE HIGHLY ATTRACTIVE
    * EXPECTS THAT THE CURRENT CASH RESOURCES WILL SUPPORT
OPERATIONS
TO H2 2024 BASED ON CURRENT PROGRAMS AND PLANS, THROUGH THE
REPORTING OF THE TOPLINE READOUTS IN INITIUM AND FOCUS
    * ULTIMOVACS IS ALSO SEEKING TO BROADEN ITS PIPELINE OF DRUG
CANDIDATES
    * NO SIGNIFICANT CHANGES HAVE OCCURRED THAT AFFECT REPORTED
RISKS

Source text for Eikon:  ID:nGNE12MxFv 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))